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Background: Artemisia annua is a Chinese medicinal herb. Artemisinin-derivatives are
recommended as part of a combination treatment for uncomplicated malaria. Herbal and
dietary supplements (HDS) are increasingly used worldwide and HDS-induced liver injury
is becoming a growing concern.
Case Report: We present the first case of severe acute cholestatic hepatitis due
to the intake of Artemisia annua tea as chemoprophylaxis for malaria in a patient
returning from Ethiopia. The patients presented with jaundice, elevated transaminases,
and parameters of cholestasis (total bilirubin 186.6 µmol/L, conjugated bilirubin 168.5
µmol/L). A liver biopsy showed a portal hepatitis with lymphocytic infiltration of the bile
ducts and diffuse intra-canalicular and intra-cytoplasmic bilirubinostasis. The toxicologic
analysis of the Artemisia tea revealed the ingredients arteannuin b, deoxyartemisin,
campher, and scopoletin. There were no other identifiable etiologies of liver disease.
The Roussel Uclaf Causality Assessment Method (RUCAM) score assessed a “probably”
causal relationship. Sequencing of genes encoding for hepatic transporters for bile acid
homeostasis (BSEP, MDR3, and FIC1) found no genetic variants typically associated with
hereditary cholestasis syndromes. Normalization of bilirubin occurred 3 months after the
onset of disease.
Conclusion: The use of artemisinin-derivatives for malaria prevention is ineffective and
potentially harmful and should thus be discouraged. Moreover, the case demonstrates
our as yet inadequate understanding of the pathophysiology and susceptibility to HDS
induced liver injury.
Keywords: acute, cholestatic liver disease, drug induced liver injury, Artemisia annua tea, artemisinin, herbal and
dietary supplement, malaria
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BACKGROUND
Artemisia annua is a Chinese medicinal herb (also known as
“qing hao” or “sweet wormwood”) with well-proven anti-malarial
activity (1). Artemisinin-derivative based combination therapies
(ACTs) are recommended by the World Health Organization
(WHO) for treatment of uncomplicated malaria in combination
with effective anti-malaria agents (2). Chemoprophylaxis for
travelers depends on the malaria-endemic travel destination and
includes a combination ofatovaquon/proguanil, chloroquine,
doxycycline, mefloquine, or primaquine (3, 4). Cases of malaria
infection under artemisinin-derivative chemoprophylaxis have
been described (5) and the WHO does not recommend the use
of A. annua plant material, in any form, including tea, for the
treatment or prevention of malaria (6).
Herbal and dietary supplements (HDS) are increasingly used
worldwide and HDS-induced liver injury is becoming a growing
concern (7). Despite the extensive use of ACTs in malaria-
endemic areas, artemisinin-derivative liver injury is rare (8, 9).
Kumar reported a case of a patient who developed a cholestatic
liver injury 6 weeks after taking a herbal supplement containing
artemisinin orally for general health maintenance (10). There are
a few other publications related to Artemisia annua - induced
liver injury (9, 11–14). A clinical guideline for evaluating the
causality and making the diagnosis of herb-induced liver injury
has recently been proposed by the Chinese Association of
Chinese Medicine (15). We present a case of an acute cholestatic
hepatitis due to intake of Artemisia tea as chemoprophylaxis in a
patient returning from Ethiopia.
CASE REPORT
A 51-year-old man presented to the emergency department
of the University Hospital of Basel, Switzerland with malaise,
abdominal discomfort, floating yellow stool, jaundice and
choluria of 4 days duration and a 6-8 kg weight loss over
the last 6 weeks. He had returned from a 4 week trip to
Ethiopia 3 weeks before seeking medical care. During his stay
in Ethiopia, he consumed 1.25 g of Artemisia annua powder-
tea on a daily basis as chemoprophylaxis for malaria. In about
90% of the cases he diluted the powder in boiling water, in the
remaining 10% the powder was ingested mixed with food. The
supplement had been purchased via the Internet. The patient
provided us with the container, which had originally contained
50 g of a dark green powder (Figure 1). At presentation 2 g
were in the container, indicating that he had consumed a total
of 48 g. During his stay in Ethiopia, he had also consumed
other tea-like preparations [black tea (Camellia sinensis) daily for
breakfast, coffee-leaf tea (once) and rita graveolens tea (twice)].
To our knowledge, there is no described hepatotoxicity related
to these substances. He denied taking any other prescription,
over-the-counter, or herbal medications. He had no previous-
or family history of liver disease, alcohol or drug abuse, or
risk factors for viral hepatitis. He reported that his wife, who
accompanied him on his trip to Ethiopia, had also consumed
Artemesia annua tea for malaria prophylaxis. She remained
well throughout.
FIGURE 1 | Artemisia annua powder tea.
Apart from marked jaundice, he was in a good general
condition and had unremarkable vital signs (afebrile with normal
blood pressure, heart rate and respiratory rate).
Laboratory tests showed: alanine aminotransferase (ALAT)
91 U/L (normal, 9-59); aspartate aminotransferase (ASAT)
42 U/L (normal, 9-34); alkaline phosphatase (ALP) 151 U/L
(normal, 40-130); gamma-glutamyl transferase (GGT) 416
U/L (normal, 12-68); total bilirubin 186.6 µmol/L (normal, 0-
24) (conjugated bilirubin 168.5 µmol/L); and international
normalized ratio (INR) 0.9 (normal, 0.9-1.3). Bile acid
level was elevated to al level of 460.5 µmol/L (normal, 0-
8.0). Differential blood count and c-reactive protein were
normal. Mild hyponatremia and hypochloremia were present,
consistent with the patient‘s increased water intake over
the previous days. Serological tests for acute hepatitis A, B,
C and E, Epstein-Barr virus and cytomegalovirus infection
were negative. Coeruloplasmin was normal. Liver-specific
auto-antibodies (anti-nuclear antibody, anti-neutrophil
antibody, anti-smooth muscle antibody, anti-mitochondrial
antibody, anti-proteinase 3 antibody and anti-myeloperoxidase
antibody) were negative and IgA, IgM and IgG were within
normal range. Abdominal ultrasonography showed a
normal liver parenchyma, vessels and biliary ducts. The
liver elastography was elevated (FibroScan, 12.7 kPa, normal
range <5 kPa).
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The patient was also evaluated at the Swiss Tropical and
Public Health Institute for various potential underlying infectious
conditions. Antibodies against rickettsia spotted fever were
positive, however, this was considered unrelated to the clinical
presentation and no antibiotic therapy was started.
The initial liver biopsy showed a portal hepatitis with
lymphocytic infiltration of the bile ducts and diffuse intra-
canalicular and intra-cytoplasmic bilirubinostasis. Neither
fibrosis nor parasitic material was seen (Figures 2A,B). A next
generation sequencing analysis on DNA from peripheral blood
leukocytes for genetic variants in the genes encoding the 3 most
important hepatic transporters for bile acid homeostasis, namely
BSEP, MDR3 and FIC1, found no variants typically associated
with hereditary cholestatic liver diseases.
The toxicologic analysis of the Artemisia tea by liquid
chromatography-mass spectrometry and gas chromatography –
mass spectrometry revealed the following ingredients: arteannuin
b, deoxyartemisin, camphor and scopoletin.
Treatment with prednisone 20mg twice daily and
ursodeoxycholic acid 500mg twice daily was initiated. Due
to persistent jaundice as well as increasing bilirubin over 4
weeks despite treatment, a second liver biopsy was performed.
The second biopsy showed a severe intracytoplasmatic as
well as intracanalicular bilirubinostasis, with only minimal
inflammation compared to the first biopsy (Figures 2C,D).
Corticosteroid treatment was discontinued, ursodeoxycholic acid
was continued until resolution of jaundice and normalization
of bilirubin (15.3 µmol/l) (Figure 3) and relevant decrease of
bile acids (19.5 µmol/l) which occurred three months after the
disease’s onset.
The case was reported to the pharmacovigilance unit of the
Swiss national authority for therapeutic products (Swissmedic).
Written informed consent was obtained from the participant for
the publication of this case report.
DISCUSSION
Artemisinin-derivatives are a cornerstone for the treatment but
not chemoprevention of malaria (2). Despite their extensive
use, artemisinin-derivative liver injury has rarely been described
(8, 10). As far as we know, this is the first case report of
an acute cholestatic hepatitis due to the intake of Artemisia
annua tea.
FIGURE 2 | Histology of the the first (A,B) and second (C,D) liver biopsy. (A) Low power view of hepatic biopsy showing a portal lymphocytic infiltrate [Hematoxylin
and eosin (HE), 10x]. (B) Liver parenchyma with intracellular bilirubinostasis (HE, 20x). (C) Low power view of hepatic biopsy without significant portal inflammation
(HE, 10x). (D) Liver parenchyma with significant intracellular and extracellular (arrow) bilirubinostasis (HE, 20x).
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FIGURE 3 | Course of bilirubin and liver enzymes over time.
FIGURE 4 | Molecular genetic analysis of the genes ABCB11, ABCB4, and ATP8B1.
Herbal and dietary supplements -induced liver injury is a topic
of growing interest since HDS are used increasingly worldwide
(7). The intake of HDS is often regarded as harmless, however,
an increasing number of adverse events occurring alongside their
use have been reported (16). Furthermore, as the concentration
and composition of HDS are often not declared on the product
labels, the quality and quantity of the product’s ingredients
remain unknown. In our case, the diagnosis of HDS-induced
liver injury due to the intake of Artemisia annua tea was
based on the strong temporal relationship between exposure and
development of the adverse reaction and the absence of other
possible etiologies. We calculated the causality assessment score
according to the RUCAM (Roussel Uclaf Causality Assessment
Method) (17) and obtained a score of 6 corresponding to a
“probable” causality of the incriminated drug. The different items
were scored as follows: time to onset (+2), course (+1), risk
factors (+1), concomitant drugs (-1), exclusion of other causes of
liver injury (+2), previous information on hepatotoxicity of the
drug (+1), response to readministration (0).There were no other
identifiable etiologies of liver disease.
Frontiers in Medicine | www.frontiersin.org 4 October 2019 | Volume 6 | Article 221
Ruperti-Repilado et al. Danger of Artemisia annua Tea
The case previously described by Kumar presented
a hepatocellular pattern of liver injury, followed by a
prolonged cholestatic phase (10). Our patient presented
with a predominantly cholestatic pattern of liver injury 5 weeks
after the first ingestion of Artemisia annua tea. We assume that
the natural history was similar to Kumar’s case, but that our
patient presented at a later stage during the evolution of liver
injury. In the toxicological analysis of the ingested herbal tea we
identified additionally scopoletin and camphor, which naturally
occur in Artemisia annua (18, 19) and may have contributed to
the onset of cholestatic liver injury.
The mechanism of artemisinin-derivative-induced liver
injury remains unclear. Chemical components of Artemisiae
spp include volatile oils, flavonoid, tannins, triterpenes and
polysaccharides. Volatile oils from Artemisiae spp have
strong pharmacological activities and toxicity, and a recent
bioinformatics approach identified various pathways that
may be involved in the development of liver injury (20).
Predisposition to drug-induced cholestatic liver injury has been
associated with bile salt export pump polymorphisms (21, 22).
We therefore searched for variants in bile acid transporters
by next generation sequencing. We did not detect a deletion,
duplication or pathologic variant in the ABCB11, ATP8B1
and ABCB4 gene sequences (coding and flanking regions)
coding for BSEP, FIC1 and MDR3, respectively (Figure 4).
However, a number of common sequence variants were
identified. Our patient harbored homozygously a variant
of the ABCB11 gene [NP_003733.2:p.(Val444Ala)]. It has
been debated whether this polymorphism is associated with
benign recurrent and/or progressive familiar intrahepatic
cholestasis and intrahepatic cholestasis of pregnancy (23, 24).
Moreover, another common variant in the ABCB11 gene was
detected in heterozygous state [NP_003733.2:p.(Ala1028=)].
This variant has been associated with reduced protein
expression (25) and with primary biliary cirrhosis (26, 27).
However, both genetic variants are much too frequent in
the general population to be causal for cholestatic liver
diseases (28). Systematic sequencing of the transcriptome
in such cases may identify variants in other regions of the
gene sequences or in other genes encoding for other hepatic
transporters or proteins involved in bile generation, such as
ABCC2, ABCC3, ABCC4, and tight junction protein 2 (TJP2),
respectively (21).
In conclusion, we describe a case of a severe HDS induced
cholestatic liver injury compatible with the intake of Artemisia
annua tea. Efforts should be undertaken to discourage the
use of artemisinin-derivatives for malaria prevention, which
is ineffective according to WHO recommendations and may
additionally cause harm. Moreover, the case demonstrates our
as yet inadequate understanding of the pathophysiology and
susceptibility to HDS induced liver injury.
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